drugset

drugset / Trial / NCT00366522

Study Evaluating LXR-623 in Healthy Subjects

NCT00366522 ↗

Phase 1 Completed Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.

Timeline

Start: 2006-08
Primary completion: 2006-09
Completion: 2006-09

Publications

Richartz J, Yam SC, Zhan N, Schepers M, Tiane A, Mulder MT, Wens I, Vanmierlo T. Liver X receptors: A therapeutic target in demyelinating disorders. Pharmacol Res. 2025 Sep;219:107861. doi: 10.1016/j.phrs.2025.107861. Epub 2025 Jul 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LXR-623	Small molecule	—	Oral

Indications

No indication recorded.